US$ 22.56
dpp 4 inhibitors and glp 1 agonists together Receptor Mechanism of Action The effect of DPP-4 inhibitors,
Description
At last there is a promising treatment for this chronic disease FDA-approved GLP-1 Anti-Obesity Medication (AOM) such as Wegovy and Saxenda but the cost implications are concerning

While patient preference is clearly shifting toward non-injectable options, injectables are projected to retain a 75% market share by 2035, not the minority
In patients with T2DM and chronic liver disease attributed to MASLD, the risk of major adverse liver outcomes after GLP-1RA treatment over 10 years fails to decrease (15.8% vs

Trulicity quickly became one of the most widely used GLP-1 RAs , especially in the U.S., due to its convenience

Lancet 2021;397:97184.ArticlePubMed 48

By the middle of 2025, several BCBS affiliates had seen enough
